Abstracts tagged "belimumab and pharmacokinetics"

Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Richard Dimelow ¹, Beulah Ji² and Herbert Struemper ³, ¹GSK, Stevenage, United Kingdom, ²GSK, Uxbridge, Middlesex, United Kingdom, ³GSK, Research Triangle Park
Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
Abstract Number: 756 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, Mita Thapar², David Gordon³ and David Roth³, ¹Quantitative Clinical Development, PAREXEL, Durham, NC, ²ICON, Marlow, United Kingdom, ³GSK, Philadelphia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting
Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Herbert Struemper¹, David Roth² and David Gordon³, ¹GlaxoSmithKline, Research Triangle Park, NC, ²GlaxoSmithKline, Philadelphia, PA, ³Immuno-Inflammation R&D, GlaxoSmithKline, King of Prussia, PA
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].